Abstract: A method and apparatus for remotely installing and executing software on a mobile device. A work item is formed that includes the software to be installed and executed, and a remote-execution command message is sent to the mobile device. The mobile device authenticates the remote-execution command message before extracting the remote-execution command and using it to request a download of the work item. The remote-execution command message is preferably an SMS message including a hook so that it is quickly recognizable as a remote-execution command message by the mobile device. When the work item arrives, it is authenticated before it is executed. When the mobile device determines that the execution is complete, it sends a notification to the remote-execution server.

Abstract: A semiconductor device is described. The device comprises a transmitter associated with a die; a package adapted to be coupled to the transmitter and operative for receiving a data signal from the transmitter, wherein the package comprises at least one package trace having at least one segment, and the segment is capacitive and is positioned a quarter wavelength away from the die; a channel adapted to be coupled to the package and operative for receiving the data signal from the package; and a receiver coupled to the channel and operative for receiving the data signal from the channel.

Abstract: A method, system, computer system and computer program product to distribute data to arbitrarily large subsets of a very large client base, with each client computer system running client software referred to as an agent. The data distribution system uses minimal server resources and a large-scale network such as the Internet. The data to be distributed may include, for example, agent software configuration data; agent software programs, plug-ins, and associated data; announcements; and other data that is centrally managed by an administrator. Using this invention, millions of client computer systems, such as computer systems for subscribers to a broadband service, can be configured and managed centrally, while allowing data to be distributed to all or a subset of subscribers efficiently and using minimal bandwidth. Agents assist in determining whether particular data are to be distributed to them, enabling much larger-scale applications to be supported with limited server-side resources.

Abstract: The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.

Abstract: The present invention relates to novel and improved compositions of anticancer drugs, preferably taxanes, such as paclitaxel and docetaxel, their derivatives or their analogues, methods of manufacturing these compositions and methods of fractionating the particles in particular size range and methods of treating cancer patients with these compositions, which provide reduced chemotherapy-induced side-effects especially reduced chemotherapy-induced-alopecia. The composition is such that there is substantially no free drug in the said composition.

Abstract: An implant assembly for creating a neural interface with a central nervous system having at least one biocompatible intracortical electrode is presented along with a method of making and implanting device. The mechanical, electrical and biological characteristics of the assembly support its use as a reliable long term implant.

Abstract: A process for producing ethers by reacting alcohols and olefins in successive catalytic stages is disclosed. The process includes alternating catalytic reaction stages and separation stages.

Abstract: The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.

Abstract: The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.

Abstract: The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.

Abstract: This invention covers a process for making Octene from nix C4 Feed by a low cost highly selective multistage process. The multi staging of reactors essentially provides lower cost than conventional processes. Two options are provided in FIGS. 1 and 2 as regards to configuration based on the same catalyst but as can be seen that FIG. 1 configuration is low cost option with very high selectivity. The process provides conversion of butene to Octene >95% and product purity >96%. Product can be fractionated and can have a high purity Octene product by removing the trimers/polymers from the octene product. As mentioned due to the nature of the process configuration, one achieves high yield and selectivity with low cost.

Abstract: A normalization engine and a method of requesting a key or performing an operation pertaining to an end point. In one embodiment, the normalization engine includes: (1) a data manager configured to receive a request to execute an operation or obtain a key/value pair pertaining to an end point and determine a normalized version of the key in the key/value pair and (2) a normalization mapping repository configured to contain normalization mechanisms, the data manager further configured to employ the normalized version to obtain one of the normalization mechanisms from the normalization mapping repository, carry out the normalization mechanism and employ a data source corresponding to the end point to retrieve a device-specific value corresponding to the normalized version.

Abstract: The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk (10) which has two compartments (14) and (18); the compartments consist of at least one active agent and at least one mucoadhesive agent and both the compartments are adapted to be in contact with the mucosal membrane. The invention also provides for transmucosal administration of an active agent and method of treatment of diseases in a subject in need of such treatment.

Abstract: The combination of low intensity pulsed ultrasound with administration of an osteogenic protein or proteins or their genes enhances bone repair in mammals. This combination avoids thermal activation of tissue repair mechanisms and allows the osteogenic protein or proteins or their genes to act at the site of bone fracture or lowered bone density to enhance or accelerate bone formation, thereby improving the prognosis of a patient. The combination may be used to treat fractures, to prevent or treat osteoporosis, to improve outcomes for bone replacement and to prevent or treat bone loss due to other physiologic disorders.

Abstract: A controlled release pharmaceutical composition for peroral administration including a single unit fast release fraction and a single unit extended release fraction which includes nimesulide as an active drug upto 99% w/w of the composition, one or more release controlling materials from 0.1% to 99% w/w of the composition and pharmaceutical excipients from 0% to 90% w/w of the composition. The nimesulide is present in the fast release fraction and in the extended release fraction.

Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating comprising water insoluble polymer(s) and leachable component(s) is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.

Abstract: This invention covers a process for making biodiesel from vegetable oils and animal fat with a simple hetrogeneous catalyst providing high yield and reaction rates under moderate conditions. The process is designed so as to enhance the yield by pretreatment step of esterification if required. The process provides gravity separation and any pretreatment/distillation/stripping, if needed before sending Biodiesel and glycerine to storage. The process provides heterogeneous catalysts so as to reduce the waste from the system and also it reduces the utilities and chemical cost. The process is optimized, simple in operation, economical, providing best yields compared to any processes in the market.

Abstract: This invention covers a process for making Octene from mix C4 Feed by a low cost highly selective multistage process. The multi staging of reactors essentially provides lower cost than conventional processes. Two options are provided in FIGS. 1 and 2 as regards to configuration based on the same catalyst but as can be seen that FIG. 1 configuration is low cost option with very high selectivity. The process provides conversion of butene to Octene >95% and product purity >96%. Product can be fractionated and can have a high purity Octene product by removing the trimers/polymers from the octene product. As mentioned due to the nature of the process configuration, one achieves high yield and selectivity with low cost.

Abstract: A process for selective hydrogenation of C3/C4/C5/C6/C7 and LCN, hydro-isomerization of olefins, benzene saturation and hydrodesulfurization of Gasoline, Kerosene and Diesel together with aromatic saturation of LCO is being provided so as to provide optimum technology at low cost with unique configuration. The technology is user friendly and uses conventional catalyst. These configurations cover both the options of installing the bulk catalyst in the distillation column with chimneys trays, hence essentially all the reaction takes place in the liquid phase in single or multiple beds or with fixed bed down flow or up flow reactor configuration. The configurations shown in the figures depicts that the fixed bed reactors are integrated with the Distillation Column and this art helps in lowering the Capital costs and the reactors are operating in single phase or two-phase conditions.

Abstract: The present invention relates to an improved oral pharmaceutical composition containing at least one poorly water soluble active agent, the active agent containing at least one of an endothelin conversion enzyme (ECE) inhibitor and a neutral endopeptidase (NEP) inhibitor in an amount greater than 10% w/w of the composition, and an alkali system comprising a mixture of at least two alkaline compounds in a ratio of from 1:20 to 20:1. The present invention also relates to an improved oral pharmaceutical composition containing, SLV-306 or at least one pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or derivative thereof, as an active agent, and an alkali system in an amount greater than 10% w/w of the composition comprising a mixture of at least two alkaline compounds and optionally at least one pharmaceutically acceptable excipient. The present invention further relates to a process for preparation of such improved compositions and methods for treatment using such compositions.